Vaccination with purified recombinant allergens in adjuvant and challenge experiment

IBH is a Th2 type, IgE mediated allergy with an imbalance between Th1, Th2 and Treg (Hamza et al., 2007; Hamza et al., 2010; Hamza et al., 2008; Heimann et al., 2011). It is therefore important to use Th1/Treg focusing adjuvants or agents to induce and/or rebalance the Th1:Th2:Treg responses and restraint the inflammatory mechanisms. The route of injection has also to be considered and we have shown that injecting directly into the lymph nodes with the appropriate adjuvant is a promising option (Jonsdottir et al., 2015; Jonsdottir et al., 2016). Vaccination with purified allergens in Alum/monophosphoryl lipid A (MPL), but not in Alum alone, resulted in a Th1/Treg focused immune response. The IgG antibodies induced efficiently blocked the binding of IgE from IBH horses to the allergens (Jonsdottir et al., 2016). It has been demonstrated that allergen-specific IgG antibodies that compete with IgE for binding to the allergens are one of the major mechanisms in successful immunotherapy.
The  intralymphatic vaccination with purified allergens in Alum/MPL was reinforced in more horses and compared to subcutaneous vaccination a more practical injection route. (Stefánsdóttir et al., manuscript in preparation).
Þú ert að nota: